Tuesday, May 15, 2018 7:24:59 AM
The trading (or lack thereof) is interesting to watch but you can't draw conclusions from any of it. A single person buying over 10,000 shares at once could make this sub-million share stock seem as if it's about to soar.
They don't need to buy based on news. They can buy (or sell, or short) for any reason. Most of the people who invest on gambling stocks invest largely on their hunches as much as anything else, I would think.
Anyway, on the recent Friday where it actually did make a huge jump, it may well have been a single investor causing the action, and if that said investor sold out of his position by mid-day the following Monday, perhaps that explains why trading has mostly stopped since... but that doesn't explain it either.
Ticker, alas, could pick up at any time. It could shoot up, or shoot down. It has to be one of the most easily manipulable stocks on the market right now. That long-term investors are trigger-shy makes sense. That short-term investors have more compelling risk/reward opportunities makes sense too (as this comes with the risk/certainty of a near-term financing, assuming buyout does not take place).
But to say that news (positive or negative) doesn't matter because the ticker did little these last few days is a conclusion you can't make IMO.
The length of this post is ridiculous, apologies to all for it. But I babbled too long to just cancel post.
They don't need to buy based on news. They can buy (or sell, or short) for any reason. Most of the people who invest on gambling stocks invest largely on their hunches as much as anything else, I would think.
Anyway, on the recent Friday where it actually did make a huge jump, it may well have been a single investor causing the action, and if that said investor sold out of his position by mid-day the following Monday, perhaps that explains why trading has mostly stopped since... but that doesn't explain it either.
Ticker, alas, could pick up at any time. It could shoot up, or shoot down. It has to be one of the most easily manipulable stocks on the market right now. That long-term investors are trigger-shy makes sense. That short-term investors have more compelling risk/reward opportunities makes sense too (as this comes with the risk/certainty of a near-term financing, assuming buyout does not take place).
But to say that news (positive or negative) doesn't matter because the ticker did little these last few days is a conclusion you can't make IMO.
The length of this post is ridiculous, apologies to all for it. But I babbled too long to just cancel post.
Recent DCTH News
- Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts • Business Wire • 05/26/2026 08:01:00 PM
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
